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Abstract: Antiepileptic drug combination therapy remains an empirical second-line treat-
ment approach in trigeminal neuralgia, after treatment with one antiepileptic drug or other 
nonantiepileptic drugs have failed. The results in three patients followed in our clinic are not 
sufficient to draw definitive conclusions, but suggest the possibility of developing this type of 
therapeutic approach further.
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Introduction
The annual incidence of trigeminal neuralgia is approximately 12.6 new cases per 
100,000 people per year, with a female to male preponderance of 3:2.1 Trigeminal 
neuralgia is defined by the International Classification of Headache Disorders as 
paroxysmal attacks of pain (strong, sharp, superficial, or stabbing) lasting from a 
fraction of a second to 2 minutes, precipitated by stimulation of “trigger zones” or 
triggers with involvement of one or more divisions of the trigeminal nerve. The age 
of onset is 40–60 years for classic trigeminal neuralgia (idiopathic, not attributed to 
another disorder) and 30–40 years for symptomatic trigeminal neuralgia (secondary 
to compression of the trigeminal ganglion or to a demyelinating disorder).
Several studies have investigated carbamazepine, gabapentin, and pregabalin for 
their effectiveness in the treatment of trigeminal neuralgia.2–4 Currently, the combina-
tion of antiepileptic drugs in the treatment of trigeminal neuralgia is a “second-line 
approach.” Antiepileptic drug treatment is sometimes considered when a combination 
of nonantiepileptic drugs fails. We report here three patients with trigeminal neuralgia 
who were successfully treated using a combination of antiepileptic drugs after failure 
of first-line and other therapeutic strategies.
Case series
The records of three patients (A, B, and C) diagnosed with trigeminal neuralgia and 
attending the Clinic for Pain Therapy at our institution were retrospectively reviewed, 
and appropriate information was collected. These patients were chosen as cases to 
report because of their refractory typical trigeminal neuralgia symptoms. Patients who 
did not require a combination of antiepileptic drugs to treat their symptoms were not 
included. The patients provided written consent for their information to be used for 
clinical research. Two patients were found to have trigeminal neuralgia secondary 
to ganglion compression (A and B) and the third patient had an idiopathic form (C). Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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The pathophysiological characteristics and therapeutic 
management of the patients are summarized in Table 1. The 
two patients with secondary trigeminal neuralgia underwent 
neurosurgical decompression of the trigeminal ganglion and 
other minimally invasive treatment (nerve block and infiltra-
tion), in addition to several sessions of acupuncture which 
did not change either in intensity or type of pain. In a differ-
ent tertiary clinic, all three patients had in the first instance 
taken antiepileptic monotherapy using various combinations 
of nonantiepileptic drugs for a period of 7 months to 8 years 
without obtaining satisfactory results in terms of pain relief, 
but experiencing various side effects due to the use of anti-
depressants (drowsiness), opioids (nausea and constipation), 
and nonsteroidal anti-inflammatory drugs (epigastralgia).
The three patients were subsequently prescribed a com-
bination of antiepileptic drugs for a period of 1–7 months. 
Carbamazepine was prescribed with gabapentin or pregaba-
lin, taking advantage of the different actions of these agents 
at various receptor levels. The dosages of all the drugs were 
lower (see Table 1) than the therapeutic dose of each drug 
when used alone, without the need for initial titration, thereby 
decreasing the potential risk of side effects. All patients 
underwent regular blood investigations to ensure consistent 
carbamazepine levels, which were always within the thera-
peutic range (4–12 mg/L).
All patients showed a marked clinical improvement 
on combination therapy (carbamazepine + gabapentin 
or   carbamazepine + pregabalin) and decided voluntarily 
to reduce or suspend treatment after remission of pain 
  symptoms, and have not reported recurrence of symptoms 
since their last follow-up visits in our clinic at 1 year. There 
have been no side effects reported following the combination 
therapy. Only one patient complained of dizziness, which 
predated the start of the antiepileptic drug combination.
Discussion
Trigeminal neuralgia causes episodes of paroxysmal pain 
that are short-lasting but intense in nature. The intervals 
between the paroxysms are generally free from painful 
symptoms, but a constant dull pain persists in some cases.5 
Medical treatment of trigeminal neuralgia includes the use of 
antiepileptic drugs (carbamazepine, gabapentin, pregabalin, 
lamotrigine) and nonantiepileptic drugs (baclofen, tocainide, 
pimozide,   clomipramine, amitriptyline, tizanidine, propa-
racaine). The most studied antiepileptic drugs in trigemi-
nal neuralgia are carbamazepine, baclofen, lamotrigine, 
and pimozide.6 Recent studies have suggested the use of 
other antiepileptic drugs in trigeminal neuralgia, such as Drug, Healthcare and Patient Safety
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gabapentin and pregabalin.2,7 No study has ever compared 
antiepileptic drug monotherapy with combination therapy 
of two antiepileptic drugs, exploiting their different actions 
at the synaptic level, although in one study polypharmacy 
has been used successfully as second-line treatment after 
eight weeks of unsuccessful monotherapy.2 It is assumed that 
carbamazepine controls paroxysmal pain by suppression of 
ectopic neuronal transmission, ie, blocking synaptic sodium 
channels, whereas gabapentin and pregabalin interact with 
the α2δ subunit of voltage-gated calcium channels by increas-
ing the brain concentration and rate of synthesis of gamma 
aminobutyric acid.8,9
There are no randomized trials demonstrating the effec-
tiveness of a combination of anticonvulsants compared with 
monotherapy or following unsuccessful monotherapy in their 
study of pregabalin. In their study of pregabalin, Obermann 
et al2 added carbamazepine 600–1200 mg/day or lamotrigine 
50–200 mg/day after eight weeks of pregabalin monotherapy. 
Although their research did not investigate the efficacy of 
combination therapy, the results showed a marked reduction 
of pain in two patients treated with anticonvulsants. The three 
patients followed in our clinic are not sufficient to draw any 
kind of conclusion, but suggest the possibility of further 
investigation of this type of therapeutic approach.
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